Early experiments indicate that this wider approach produces more powerful, persistent outcomes for many users
Deal of the Week Regeneron will pay Tessera Pharmaceuticals $150 million upfront as part of a gene-editing partnership for a rare liver and lung disease, known as alpha-1 antitrypsin deficiency
FDA Commissioner Marty Makary stated plainly that affordability and insurance access do not constitute clinical need under the law
Youll still need healthy fats, protein, essential vitamins, and nutrients, and energizing calories
As a DTC telehealth player, you have to be involved in the market even if the GLP-1 boost functions as a short-term cash grab
Debates about agency, personal responsibility, body shaming, and ultra-processed foods dominated